SG11201909840TA - Treatment of epithelial cysts by intracystic injection of antineoplastic particles - Google Patents

Treatment of epithelial cysts by intracystic injection of antineoplastic particles

Info

Publication number
SG11201909840TA
SG11201909840TA SG11201909840TA SG11201909840TA SG 11201909840T A SG11201909840T A SG 11201909840TA SG 11201909840T A SG11201909840T A SG 11201909840TA SG 11201909840T A SG11201909840T A SG 11201909840TA
Authority
SG
Singapore
Prior art keywords
crititech
lawrence
road
international
particles
Prior art date
Application number
Inventor
Gere Dizerega
Michael Baltezor
Charles Decedue
Sam Campbell
Matthew Mcclorey
Marc Iacobucci
Holly Maulhardt
Original Assignee
Crititech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crititech Inc filed Critical Crititech Inc
Publication of SG11201909840TA publication Critical patent/SG11201909840TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
    • A61B8/0833—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
    • A61B8/0841—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures for locating instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/12—Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 December 2018 (13.12.2018) WIP0 I PCT omit VIII °nolo Homolomoimoommom (10) International Publication Number WO 2018/227037 Al (51) International Patent Classification: A61P 35/00 (2006.01) A61K 31/337 (2006.01) A61K 9/00 (2006.01) A61P 1/18 (2006.01) A61K 9/19 (2006.01) (21) International Application Number: PCT/US2018/036587 (22) International Filing Date: 08 June 2018 (08.06.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/517,711 09 June 2017 (09.06.2017) US (71) Applicant: CRITITECH, INC. [US/US]; 1849 E. 1450 Road, Lawrence, KS 66044 (US). (72) Inventors: DIZEREGA, Gere; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). BALTEZOR, Michael; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). DECEDUE, Charles; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). CAMP- BELL, Sam; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). MCCLOREY, Matthew; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). IACOBUCCI, Marc; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). MAULHARDT, Holly; c/o Crititech, Inc., 1849 E. 1450 Road, Lawrence, KS 66044 (US). (74) Agent: HARPER, David S.; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Chicago, IL 60606 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (84) Designated States 11 N O N (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 00 (54) Title: TREATMENT OF EPITHELIAL CYSTS BY INTRACYSTIC INJECTION OF ANTINEOPLASTIC PARTICLES 0 (57) : Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection \" of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
SG11201909840T 2017-06-09 2018-06-08 Treatment of epithelial cysts by intracystic injection of antineoplastic particles SG11201909840TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762517711P 2017-06-09 2017-06-09
PCT/US2018/036587 WO2018227037A1 (en) 2017-06-09 2018-06-08 Treatment of epithelial cysts by intracystic injection of antineoplastic particles

Publications (1)

Publication Number Publication Date
SG11201909840TA true SG11201909840TA (en) 2019-11-28

Family

ID=62779068

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913649TA SG10201913649TA (en) 2017-06-09 2018-06-08 Treatment of epithelial cysts by intracystic injection of antineoplastic particles
SG11201909840T SG11201909840TA (en) 2017-06-09 2018-06-08 Treatment of epithelial cysts by intracystic injection of antineoplastic particles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913649TA SG10201913649TA (en) 2017-06-09 2018-06-08 Treatment of epithelial cysts by intracystic injection of antineoplastic particles

Country Status (11)

Country Link
US (4) US20190254957A1 (en)
EP (1) EP3615145A1 (en)
JP (1) JP2020523285A (en)
KR (1) KR20200014279A (en)
CN (1) CN110730679A (en)
AU (1) AU2018279634A1 (en)
BR (1) BR112019023948A2 (en)
CA (1) CA3063420A1 (en)
RU (1) RU2019134145A (en)
SG (2) SG10201913649TA (en)
WO (1) WO2018227037A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2750163C2 (en) 2015-06-04 2021-06-22 Крититек, Инк. Taxan particles and their application
RU2737934C2 (en) 2016-04-04 2020-12-07 Крититек, Инк. Methods of treating solid tumors
SG10201913649TA (en) 2017-06-09 2020-03-30 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CA3063436A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
CN111278436A (en) 2017-10-03 2020-06-12 克里蒂泰克公司 Local delivery of anti-tumor particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
KR102526793B1 (en) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 Method for preparing albumin bound taxane nanoparticles with improved particle size distribution maintenance stability

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
EP3266450A1 (en) * 1997-06-27 2018-01-10 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
IL133672A0 (en) 1997-06-27 2001-04-30 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP3418751B2 (en) 1998-01-22 2003-06-23 参天製薬株式会社 Fluorometholone suspension ophthalmic solution
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
EP1131063B1 (en) 1998-11-25 2003-04-23 Universitätsklinikum Freiburg Hyperforin ointment or cream
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
ATE312601T1 (en) 1999-05-27 2005-12-15 Acusphere Inc POROUS MEDICINAL MATRICES AND THEIR PRODUCTION PROCESS
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6616849B1 (en) 1999-08-25 2003-09-09 Shimadzu Corporation Method of and system for continuously processing liquid materials, and the product processed thereby
CA2388844A1 (en) 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6562952B1 (en) 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US20020081339A1 (en) 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
CA2445763A1 (en) 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
EP1401563B2 (en) 2001-07-02 2015-09-16 Micro & Nano Materials SAGL Process for the production of micro and/or nano particles
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
ES2625340T3 (en) 2001-10-15 2017-07-19 Crititech, Inc. Compositions and methods for the administration of poorly water soluble drugs and treatment methods
WO2003043586A2 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
EP1480691A4 (en) 2002-03-05 2007-11-28 Univ State Cleveland Agglomerated particles for aerosol drug delivery
CA2479665C (en) 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
GB2387781A (en) 2002-04-25 2003-10-29 Nektar Therapeutics Uk Ltd Particulate materials
CA2482941A1 (en) 2002-04-26 2003-11-06 Teva Pharmaceutical Industries Ltd. Microparticle pharmaceutical compositions for intratumoral delivery
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CN1255394C (en) 2002-06-24 2006-05-10 成都思摩纳米技术有限公司 Process for the manufacture of pacilitaxel nano granule
KR100573289B1 (en) 2002-07-20 2006-04-24 대화제약 주식회사 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof
JP2006514698A (en) 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド Nanoparticle bioactive substances
KR100508518B1 (en) 2002-11-13 2005-08-17 한미약품 주식회사 Method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US7455797B2 (en) 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
AU2004228008B2 (en) 2003-04-03 2008-11-06 Jessie L.-S. Au Tumor-targeting drug-loaded particles
US20060147535A1 (en) 2003-04-16 2006-07-06 Poongunran Muthukumaran Methods for and compositions of anticancer medicaments
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
JP2007001865A (en) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd Fine particle enclosing fat-soluble medicine, method for producing the same and preparation containing the same
DK2286794T3 (en) 2003-10-15 2016-07-25 Syncore Biotechnology Co Ltd USE OF CATIONIC LIPOSOMES, WHICH INCLUDES paclitaxel
WO2005042219A1 (en) 2003-10-24 2005-05-12 Ferro Corporation Method of forming particles
ES2366646T3 (en) 2003-11-05 2011-10-24 Elan Pharma International Limited COMPOSITIONS IN THE FORM OF NANOPARTICLES THAT HAVE A PEPTIDE AS A SURFACE STABILIZER.
GB0402963D0 (en) 2004-02-11 2004-03-17 Univ Nottingham Counter current mixing device for two different fluids
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
WO2006046670A1 (en) 2004-10-29 2006-05-04 Nara Machinery Co., Ltd. Method of granulating fine particles
US20060159712A1 (en) 2004-12-14 2006-07-20 Transave, Inc. Lipid particles comprising bioactive agents, methods of preparing and uses thereof
ES2265262B1 (en) 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) PROCEDURE FOR OBTAINING MICRO- AND NANODISPERSE SYSTEMS.
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20080003322A (en) 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 Nanoparticulate formulations of docetaxel and analogues thereof
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
KR20140014294A (en) 2005-03-31 2014-02-05 리드스 에이비 Method for treating prostate diseases based on local delivery of active substances
CN1923189A (en) 2005-08-30 2007-03-07 孔庆忠 Taxine kind anti-cancer slow release injection
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009518167A (en) 2005-12-11 2009-05-07 エスセーエフ テクノロジーズ アクティーゼルスカブ Manufacture of nano-sized materials
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
AR054215A1 (en) 2006-01-20 2007-06-13 Eriochem Sa A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT
CN101336899A (en) 2006-01-25 2009-01-07 济南帅华医药科技有限公司 Anticancer sustained-released injection containing taxane
JP5216601B2 (en) 2006-03-14 2013-06-19 リッズ エービー Bioabsorbable controlled release composition
ES2390183T3 (en) 2006-10-11 2012-11-07 Crititech, Inc. Method of precipitation of small particles of medicine in use container
TWI405590B (en) 2007-04-06 2013-08-21 Activus Pharma Co Ltd Method of producing pulverized organic compound particle
EP3326630A3 (en) 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
WO2009006590A2 (en) 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Docetaxel process and polymorphs
CN101129338A (en) 2007-08-27 2008-02-27 四川大学 Minuteness anti-cancer medicine paclitaxel of novel technique supercritical fluid
MX2010009670A (en) 2008-03-06 2010-09-22 Nitto Denko Corp Polymer paclitaxel conjugates and methods for treating cancer.
CN102149410B (en) 2008-09-19 2014-05-14 株式会社活效制药 Composite organic compound powder for medical use, method for producing same and suspension of same
JP2012510489A (en) * 2008-12-02 2012-05-10 バイオコンパティブルズ ユーケー リミテッド Treatment of pancreatic cancer
PT104693B (en) 2009-07-27 2011-11-24 Univ Lisboa SEMI-SOLID LIPID NANOPARTICLES CONTAINING AN ANTINEOPLASTIC AGENT AND ITS PREPARATION PROCESS
EP2470644B1 (en) 2009-08-24 2016-09-21 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
CN101829061A (en) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 Taxol nanoparticle composition and preparation method thereof
JP2013527232A (en) 2010-06-02 2013-06-27 アブラクシス バイオサイエンス， エルエルシー How to treat bladder cancer
ES2776983T3 (en) 2010-09-21 2020-08-03 Cristal Delivery B V Tunable biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith
US20150093440A1 (en) 2010-10-15 2015-04-02 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
WO2012096995A2 (en) 2011-01-11 2012-07-19 Boston Scientific Scimed, Inc. Coated medical devices
ES2629187T3 (en) 2011-04-20 2017-08-07 The University Of Sydney Particle material and cellular toxin for use in the treatment of a solid tumor
US20140154269A1 (en) 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
SG10201605008TA (en) 2011-06-17 2016-07-28 Berg Llc Inhalable pharmaceutical compositions
EP2723388B1 (en) 2011-06-27 2021-04-14 Cristal Delivery B.V. Controlled release system
FR2980683B1 (en) 2011-09-30 2014-11-21 Univ Paris Curie DEVICE FOR GUIDING A MEDICAL INSTRUMENT INSERTED IN A NATURAL PATH OR AN ARTIFICIAL PATH OF A PATIENT
CN102488682A (en) 2011-11-22 2012-06-13 四川九章生物化工科技发展有限公司 New application of chlorogenic acid in cancer resisting
WO2013166487A1 (en) 2012-05-04 2013-11-07 Yale University Highly penetrative nanocarriers for treatment of cns disease
TW201408304A (en) 2012-08-31 2014-03-01 Cathay General Hospital A combined drug with anti-cancer drug and hormone to treat renal cell carcinoma and its method of fabrication
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2898408C (en) 2013-02-28 2018-01-02 Pfizer Inc. Enhanced stability of novel liquid compositions
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
US9925512B2 (en) 2013-03-14 2018-03-27 Crititech, Inc. Equipment assembly for and method of processing particles
EP2978420A4 (en) 2013-03-28 2016-12-21 Bbs Nanotechnology Ltd Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
EP2983730B1 (en) 2013-04-10 2019-10-16 Massachusetts Institute of Technology Local drug delivery devices and methods for treating cancer
US10188738B2 (en) 2013-10-16 2019-01-29 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
EP3083692B1 (en) 2013-12-17 2020-02-19 F.Hoffmann-La Roche Ag Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2015103005A1 (en) * 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
TWI601542B (en) 2014-04-18 2017-10-11 林信湧 Inhalation-type pharmaceutical composition for lung cancer and preparation method thereof
WO2015187194A1 (en) 2014-06-01 2015-12-10 Crititech, Inc. Use of paclitaxel particles
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
RU2750163C2 (en) 2015-06-04 2021-06-22 Крититек, Инк. Taxan particles and their application
BR112018005200A2 (en) 2015-09-16 2018-10-09 Dfb Soria Llc release of drug nanoparticles and methods of using them
CN108135917B (en) * 2015-09-25 2021-07-09 Zy医疗 Pharmaceutical formulations based on particles comprising polysaccharide-vitamin conjugates
DE202016006620U1 (en) 2015-10-28 2017-04-12 Qass Gmbh Devices for observing a magnetic field of a material volume
SG11201805186VA (en) 2016-01-20 2018-07-30 Fate Therapeutics Inc Compositions and methods for immune cell modulation in adoptive immunotherapies
RU2737934C2 (en) 2016-04-04 2020-12-07 Крититек, Инк. Methods of treating solid tumors
CN107281502B (en) 2016-04-05 2021-05-04 上海市肿瘤研究所 Composite developing temperature-sensitive gel suppository, preparation method and application thereof
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP4177271A1 (en) 2016-09-01 2023-05-10 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
CN110636833A (en) 2017-03-15 2019-12-31 Dfb索里亚有限责任公司 Topical therapy using taxane nanoparticles for the treatment of skin malignancies
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
SG10201913649TA (en) 2017-06-09 2020-03-30 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CA3063436A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders

Also Published As

Publication number Publication date
US20230111288A1 (en) 2023-04-13
EP3615145A1 (en) 2020-03-04
CA3063420A1 (en) 2018-12-13
CN110730679A (en) 2020-01-24
RU2019134145A (en) 2021-07-09
US11523983B2 (en) 2022-12-13
US11737972B2 (en) 2023-08-29
WO2018227037A1 (en) 2018-12-13
US20190254957A1 (en) 2019-08-22
SG10201913649TA (en) 2020-03-30
AU2018279634A1 (en) 2019-10-31
US20230372234A1 (en) 2023-11-23
BR112019023948A2 (en) 2020-06-09
KR20200014279A (en) 2020-02-10
US20210259959A1 (en) 2021-08-26
JP2020523285A (en) 2020-08-06

Similar Documents

Publication Publication Date Title
SG11201909840TA (en) Treatment of epithelial cysts by intracystic injection of antineoplastic particles
SG11201808125RA (en) Methods for solid tumor treatment
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201811432WA (en) Rna for cancer therapy
SG11201909837YA (en) Methods for treating lung disorders
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201808693WA (en) Anti-il-33 antibodies, compositions, methods and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201901126UA (en) Combination therapy for cancer
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201805229YA (en) Means and methods for treating hbv
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones